Treatment resistant schizophrenia: Course of brain structure and function

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 70, Issue , 2016, Pages 111-116

  Harvey, Philip D ^a,b   Rosenthal, Jennifer B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clozapine; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; BONE MARROW SUPPRESSION; BRAIN ATROPHY; BRAIN FUNCTION; BRAIN SIZE; CORTICAL THICKNESS (BRAIN); DIABETIC KETOACIDOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GRAY MATTER; HIPPOCAMPUS; HUMAN; METABOLIC SYNDROME X; MYOCARDITIS; NEUROANATOMY; NEUROTOXICITY; PATIENT COMPLIANCE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE; TREATMENT DURATION; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT RESPONSE; WEIGHT GAIN; BRAIN; DRUG RESISTANCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE PROGRESSION; DRUG RESISTANCE; HUMANS; SCHIZOPHRENIA;

EID: 84959452761     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.02.008     Document Type: Review

References (64)

1. Ahmed, M., Cannon, D.M., Scanlon, K., et al. Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment. Neuropsychopharmacology 30 (2015), 2409–2417.
2. Ahmed, M., Hussain, J., O'Brien, S.M., et al. Prevalence and associations of the metabolic syndrome among schizophrenia patients prescribed clozapine. Ir. J. Med. Sci. 177 (2008), 205–210.
3. Andreasen, N.C., Liu, D., Ziebell, S., et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 170 (2013), 609–615.
4. Boonstra, G., Cahn, W., Schnack, H.G., et al. Duration of untreated illness in schizophrenia is not associated with 5-year brain volume change. Schizophr. Res. 132 (2011), 84–90.
5. Bowie, C.R., Reichenberg, A., McClure, M.M., et al. Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: differential sensitivity of neuropsychological and information processing tests. Schizophr. Res. 106 (2008), 50–58.
6. Buchanan, R.W., Javitt, D.C., Marder, S.R., et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164 (2007), 1593–1602.
7. Cahn, W., van Haren, N.E., Hulshoff Pol, H.E., et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br. J. Psychiatry 189 (2006), 381–382.
8. Carpenter, W.T. Jr., Arango, C., Buchanan, R.W., et al. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol. Psychiatry 46 (1999), 352–360.
9. Carpenter, W.T. Jr., Heinrichs, D.W., Wagman, A.M., Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145 (1988), 578–583.
10. Casiero, O., Perez-Iglesias, R., Mata, I., et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J. Psychiatr. Res. 46 (2012), 1099–1195.
11. Davis, K.L., Buchsbaum, M.S., Shihabuddin, L., et al. Ventricular enlargement in poor outcome schizophrenia. Biol. Psychiatry 43 (1998), 783–793.
12. De Bartolomeis, A., Balletta, R., Giordano, S., et al. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 210 (2013), 387–395.
13. Delisi, L., Sakuma, M., Tew, W., et al. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of psychosis. Psychiatry Res. Brain Imaging 74 (1997), 129–140.
14. Friedman, J., Harvey, P.D., Coleman, T., et al. A six year follow-up study of cognitive and functional status across the life-span in schizophrenia: a comparison with Alzheimer's disease and healthy subjects. Am. J. Psychiatry 158 (2001), 1441–1448.
15. Frydecka, D., Beszłej, J.A., Gościmski, P., et al. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. 235 (2016), 133–138.
16. Fusar-Poli, P., Smieskova, R., Kempton, M.J., et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci. Biobehav. Rev. 37 (2013), 1680–1691.
17. Fucetola, R., Seidman, L.J., Kremen, W.S., et al. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol. Psychiatry 48 (2000), 137–146.
18. Galderisi, S., Rossi, A., Rocca, P., et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 13 (2014), 275–287.
19. Granholm, E., Link, P., Fish, S., et al. Age-related practice effects across longitudinal neuropsychological assessments in older people with schizophrenia. Neuropsychology 24 (2010), 616–624.
20. Gur, R.E., Cowell, P., Turetsky, B.I., et al. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch. Gen. Psychiatry 55 (1998), 145–152.
21. Harvey, P.D., Bellack, A.S., Toward a terminology of functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr. Bull. 35 (2009), 300–306.
22. Harvey, P.D., Reichenberg, A., Bowie, C.R., et al. The course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous history of long-term institutional Stay. Biol Psychiat 67 (2010), 933–939.
23. Harvey, P.D., Bertisch, H., Friedman, J.I., et al. The course of functional decline in geriatric patients with schizophrenia: cognitive–functional and clinical symptoms as determinants of change. Am. J. Geriatr. Psychiatry 11 (2003), 610–619.
24. Harvey, P.D., Silverman, J.M., Mohs, R.C., et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol. Psychiatry 45 (1999), 32–40.
25. Ho, B.C., Andreasen, N.C., Nopoulos, P., et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 60 (2003), 585–594.
26. Iasevoli, F., Giordano, S., Balletta, R., et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 65 (2016), 34–48 (Feb 4).
27. Itil, T., Keskiner, A., Fink, M., Therapeutic studies in “therapy resistant” schizophrenic patients. Compr. Psychiatry 7 (1966), 488–493.
28. Kane, J., Honigfeld, G., Singer, J., et al. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with clozapine. Arch. Gen. Psychiatry 45 (1988), 789–796.
29. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
30. Keefe, R.S.E., Mohs, R.C., Losonczy, M., et al. Characteristics of very poor outcome schizophrenia. Am. J. Psychiatry 144 (1987), 889–895.
31. Kirkpatrick, B., Buchanan, R.W., Anhedonia and the deficit syndrome of schizophrenia. Psychiatry Res 31 (1989), 25–30.
32. Kirkpatrick, B., Buchanan, R.W., McKenney, P.D., et al. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30 (1989), 119–124.
33. Kirkpatrick, B., Fenton, W.S., Carpenter, W.T. Jr., et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32 (2006), 214–219.
34. Kirkpatrick, B., Kopelowicz, A., Buchanan, R.W., et al. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 22 (2000), 303–310.
35. Lappin, J.M., Morgan, C., Chalavi, S., et al. Bilateral hippocampal increase following first-episode psychosis is associated with good clinical, functional and cognitive outcomes. Psychol. Med., 2013, 1–13.
36. Levine, S.Z., Lurie, I., Kohn, R., Levav, I., Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr. Res. 126 (2011 Mar), 184–191.
37. Levine, S.Z., Rabinowitz, J., Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr. Bull. 3:6 (2010), 624–632 (May).
38. Lieberman, J.A., Alvir, J.M., Koreen, A., et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 14 (1996), 13s–21s.
39. Lieberman, J.A., Tollefson, G.D., Charles, C., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62 (2005), 361–370.
40. Marder, S.R., Overview of partial compliance. J. Clin. Psychiatry 64:Suppl. 16 (2003), 3–9.
41. Marder, S.R., Rabinowitz, J., Kapur, S., Clinical trials for negative symptoms–emerging directions and unresolved issues. Schizophr Res, 150, 2013, 32.
42. Mathalon, D.H., Sullivan, E.V., Lim, K.O., et al. Progressive brain volume changes and the course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 58 (2001), 148–157.
43. McEvoy, J.P., Lieberman, J.A., Stroup, T.S., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 (2006), 600–610.
44. Miller, B.J., Buckley, P.F., Medical and psychiatric comorbidities: complicating treatment expectations. Buckley, P.F., Gaughran, F., (eds.) Treatment Refractory Schizophrenia: A Clinical Conundrum, 2014, Springer, New York, 45–64.
45. Molina Rodriguez, V., Andree, R.M., Castejon, M.J., et al. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res. 76 (1997), 51–61.
46. Molina Rodriguez, V., Reig, S., Sanz, J., et al. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr. Res. 80 (2005), 61–71.
47. Nakajima, S., Takeuchi, H., Plitman, E., et al. Neuroimaging findings in treatment-resistant schizophrenia: a systematic review: lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr. Res. 164:1–3 (2015), 164–175.
48. Nordon, S., Rouillon, F., Azorin, J.M., et al. Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatr. Scand. 129 (2014), 116–125.
49. Overall, J.E., Gorham, D.R., The brief psychiatric rating scale. Psychol. Rep. 10 (1962), 799–812.
50. Reichenberg, A., Feo, C., Prestia, D., et al. The course and correlates of everyday functioning in schizophrenia. Schizophrenia Research: Cognition 1 (2014), 47–52.
51. Robinson, D., Woerner, M.G., Alvir, J.M., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56 (1999), 241–247.
52. Robinson, D.G., Woerner, M.G., Alvir, J.M., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 156 (1999), 544–549.
53. Strassnig, M.T., Harvey, P.D., Treatment resistance and other complicating factors in the management of schizophrenia. CNS Spectr. 19:Supplement 1 (2014), 13–24.
54. Strassnig, M.T., Raykov, T., O'Gorman, C., et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr. Res. 165 (2015), 76–82.
55. Suzuki, T., Remington, G., Mulsant, B.H., et al. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr. Res. 133 (2011), 54–62.
56. Suzuki, T., Remington, G., Mulsant, B.H., et al. Defining treatment resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 197 (2012), 1–6.
57. Tiihonen, J., Lonnqvist, J., Wahlbeck, K., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study. Lancet 374 (2007), 620–627.
58. Tracey, D.K., ShergillSS, Treatment refractory schizophrenia: Definition and Assessment. Buckley, P., Gaughran, F., (eds.) Treatment resistant schizophrenia: A clinical Conundrum, 2013, Springer, New York, 1–19.
59. Van Haren, N.E., Hulshoff Pol, H.E., Schnack, H.G., et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 32 (2007), 2057–2066.
60. van Haren, N.E., Schnack, H.G., Cahn, W., et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry 68 (2011), 871–880.
61. Ventura, J., Subotnik, K.L., Gitlin, M.J., et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr. Res. 161 (2015), 407–411.
62. Wyatt, R.J., Neuroleptics and the natural course of schizophrenia. Schizophr. Res. 17 (1991), 325–350.
63. Wyatt, R.J., Green, M.F., Tuma, A.H., Long-term morbidity associated with delayed treatment of first admission schizophrenic patients. A reanalysis of the Camarillo State Hospital data. Psychol. Med. 27 (1997), 261–268.
64. Wyatt, R.J., Henter, I.D., The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J. Psychiatr. Res. 32 (1998), 169–177.